IDEXX Laboratories (NASDAQ:IDXX) Coverage Initiated at Barclays

Barclays began coverage on shares of IDEXX Laboratories (NASDAQ:IDXX) in a research note issued to investors on Monday, MarketBeat.com reports. The firm set an “overweight” rating and a $850.00 price target on the stock. Barclays‘s price target indicates a potential upside of 20.89% from the stock’s previous close.

A number of other research analysts also recently issued reports on the company. Piper Sandler restated a “neutral” rating and issued a $700.00 price objective (up previously from $510.00) on shares of IDEXX Laboratories in a research report on Monday, August 11th. JPMorgan Chase & Co. boosted their target price on shares of IDEXX Laboratories from $675.00 to $775.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Wall Street Zen lowered shares of IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Saturday, November 29th. BTIG Research increased their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Finally, Stifel Nicolaus set a $775.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. Eight research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and a consensus target price of $763.50.

IDEXX Laboratories Stock Up 0.6%

IDXX stock opened at $703.14 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.18 and a quick ratio of 0.87. The firm’s fifty day simple moving average is $678.66 and its 200-day simple moving average is $616.60. IDEXX Laboratories has a 12 month low of $356.14 and a 12 month high of $769.98. The company has a market capitalization of $56.15 billion, a P/E ratio of 55.76, a price-to-earnings-growth ratio of 4.22 and a beta of 1.67.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings results on Monday, November 3rd. The company reported $3.22 earnings per share for the quarter, topping the consensus estimate of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to the consensus estimate of $1.07 billion. IDEXX Laboratories had a return on equity of 67.78% and a net margin of 24.65%.The firm’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same period last year, the firm earned $2.80 EPS. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities research analysts forecast that IDEXX Laboratories will post 11.93 earnings per share for the current year.

Insider Buying and Selling

In other IDEXX Laboratories news, EVP Nimrata Hunt sold 9,425 shares of the firm’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This trade represents a 30.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.98% of the company’s stock.

Institutional Trading of IDEXX Laboratories

Large investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC lifted its position in IDEXX Laboratories by 2.5% during the third quarter. EverSource Wealth Advisors LLC now owns 621 shares of the company’s stock worth $397,000 after buying an additional 15 shares in the last quarter. STF Management LP boosted its holdings in IDEXX Laboratories by 1.3% in the 2nd quarter. STF Management LP now owns 1,240 shares of the company’s stock valued at $665,000 after purchasing an additional 16 shares during the last quarter. Clearstead Trust LLC raised its position in IDEXX Laboratories by 1.1% in the second quarter. Clearstead Trust LLC now owns 1,515 shares of the company’s stock valued at $813,000 after purchasing an additional 16 shares during the period. MassMutual Private Wealth & Trust FSB raised its holdings in IDEXX Laboratories by 4.4% in the 3rd quarter. MassMutual Private Wealth & Trust FSB now owns 380 shares of the company’s stock valued at $243,000 after buying an additional 16 shares during the period. Finally, Moss Adams Wealth Advisors LLC lifted its holdings in shares of IDEXX Laboratories by 3.3% in the 3rd quarter. Moss Adams Wealth Advisors LLC now owns 528 shares of the company’s stock worth $337,000 after acquiring an additional 17 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.